Advertisement

Selenomethionine and Methioninase: Selenium Free Radical Anticancer Activity

  • Julian E. SpallholzEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1866)

Abstract

Colloidal selenium, was first used to treat cancer as early as 1911 in both humans and mice. Selenium was identified as the toxic component in forage plants of sheep, cattle, and horses in the 1930s. The animal toxicity of selenium compounds was determined to be from the metabolism by animals of the elevated concentrations of Se-methylselenocysteine and selenomethionine in plants. The metabolism of both Se-methylselenocysteine and selenomethionine by animals gives rise to the metabolite, methylselenide (CH3Se-), which if in sufficient concentration oxidizes thiols and generates superoxide and other reactive oxygen species. Cancer cells that may overly express methionine gamma-lyase, or beta-lyase (methioninase), by induced viral genomic expression, are susceptible to free radical-induced apoptosis from selenomethionine or Se-methylselenocysteine supplementation.

Key words

Selenium Selenide Selenomethionnie Cancer Prevention Therapy 

Notes

Dedication/Acknowledgments

This chapter is dedicated to Edgar N. Drake, PhD (1937–2017). Dr. Ed Drake was Chair and Professor of Chemistry at Angelo State University for many years. As an analytical chemist, he became interested in selenium analyses, and selenium as a chemoprevention dietary supplement. In 2001 he authored a book, “Selenium: Are You Getting Enough to Reduce Your Risk of Cancer?” He was thoroughly versed in selenium biochemistry and one of the early selenium scientists to recognize the pro-oxidant properties of selenium compounds (see Ref. 37). Following retirement, Ed and his wife Nina lived for many years in Estes Park, Colorado, and had a “Million-Dollar View” of Long’s Peak in Rocky Mountain National Park. The author and his wife visited Ed and Nina in Estes Park both in summer and winter, where selenium was always a major conversation topic. He will be missed by the selenium community and the people that knew him.

References

  1. 1.
    Dingwall D (1962) Selenium analogues of biologically active sulphur compounds. Pharm Pharmacol 14:765–778CrossRefGoogle Scholar
  2. 2.
    Hurd-Karrer AM (1933) Inhibition of selenium injury to wheat pants by sulfur. Science 78:560CrossRefGoogle Scholar
  3. 3.
    Ochoa-Solano A, Gitler C (1968) Incorporation of 75Se-selenomethionine and 35S-methionine into chicken egg white proteins. J Nutr 94:243–248CrossRefGoogle Scholar
  4. 4.
    Mackowiak CL, Amacher MC (2008) Soil sulfur amendments suppress selenium uptake by alfalfa and western wheatgrass. J Environ Qual 37:772–779CrossRefGoogle Scholar
  5. 5.
    Milner JA (1979) Assessment of the essentiality of methionine, threonine, tryptophan, histidine and isoleucine in immature dogs. J Nutr 109:1351–1357CrossRefGoogle Scholar
  6. 6.
    McConnell KP, Hoffman JL (1972) Methionine-selenomethionine parallels in rat liver polypeptide chain synthesis. FEBS Lett 24:60–62CrossRefGoogle Scholar
  7. 7.
    Franke KW (1934) A new toxicant occurring naturally in certain samples of plant foodstuffs. J Nutrition 8:597–608CrossRefGoogle Scholar
  8. 8.
    Whanger PD (2002) Selenocompounds in plants and animals and their biological significance. J Am Coll Nutr 21:223–232CrossRefGoogle Scholar
  9. 9.
    Böck A, Forchhammer K, Heider J et al (1991) Selenocysteine: the 21st amino acid. Mol Microbiol 5:515–520CrossRefGoogle Scholar
  10. 10.
    Rotruck JT, Pope AL, Ganther HE et al (1973) Selenium: biochemical role as a component of glutathione peroxidase. Science 179:588–590CrossRefGoogle Scholar
  11. 11.
    Schwarz K, Foltz CM (1958) Factor 3 activity of selenium compounds. J Biol Chem 233:245–251PubMedGoogle Scholar
  12. 12.
    Jukes TH (1983) Selenium, an “essential poison”. J Appl Biochem 5:233–234PubMedGoogle Scholar
  13. 13.
    Seko Y, Saito Y, Kitahara J, Imura N et al (1989) Active oxygen generation by the reaction of selenite with reduced glutathione in vitro. In: Wendel A (ed) Selenium in biology and medicine. Springer, Berlin Heidelberg; Tubingen, pp 70–73CrossRefGoogle Scholar
  14. 14.
    Kitahara J, Seko Y, Imura N (1993) Possible involvement of active oxygen species in selenite toxicity in isolated rat hepatocytes. Arch Toxicol 67:497–501CrossRefGoogle Scholar
  15. 15.
    Seko Y, Imura N (1997) Active oxygen generation as a possible mechanism of selenium toxicity. Biomed Environ Sci 10:333–339PubMedGoogle Scholar
  16. 16.
    Chaudière J, Courtin O, Leclaire J (1992) Glutathione oxidase activity of selenocystamine: a mechanistic study. Arch Biochem Biophys 296:328–336CrossRefGoogle Scholar
  17. 17.
    Chen JJ, Boylan LM, Wu CK et al (2007) Oxidation of glutathione and superoxide generation by inorganic and organic selenium compounds. Biofactors 31:55–66CrossRefGoogle Scholar
  18. 18.
    Spallholz JE (1994) On the nature of selenium toxicity and carcinostatic activity. Free Radic Biol Med 17:45–64CrossRefGoogle Scholar
  19. 19.
    Shriver BJ, Praytor LM, Boylan LM et al (2000) Response of growing rats to supplemental selenium in the form of L-Se-methylselenocysteine or L-selenomethionine. FASEB J 14:A513Google Scholar
  20. 20.
    Berzelius JJ (1817) Sur deux metaux nouveaux (litium et selenium). Schweigger J 2:1818–1823Google Scholar
  21. 21.
    Letter May 6, 1912. In references to a publication to the use of selenium to treat a tongue epithelioma; Le Province Medicale; 13 April 1912 (Paris)Google Scholar
  22. 22.
    Sugiura K, Benedict SR (1929) The action of certain dyestuffs on the growth of transplantable tumors. J Cancer Res 13:340 Wasserman A, Keyser FGoogle Scholar
  23. 23.
    Schwarz K, Foltz CM (1957) Selenium as an integral part of factor 3 against dietary necrotic liver degeneration. J Am Chem Soc 79:3292–3293CrossRefGoogle Scholar
  24. 24.
    Shamberger RJ, Frost DV (1969) Possible protective effect of selenium against human cancer. Can Med Assoc J 100:682PubMedPubMedCentralGoogle Scholar
  25. 25.
    Frost DV, Lish PM (1975) Selenium in biology. Annu Rev Pharmacol 15:259–284CrossRefGoogle Scholar
  26. 26.
    Clark LC, Cantor KP, Allaway WH (1991) Selenium in forage crops and cancer mortality in U.S. counties. Arch Environ Health 46:37–42CrossRefGoogle Scholar
  27. 27.
    Clark LC, Combs GF Jr, Turnbull BW et al (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276:1957–1963CrossRefGoogle Scholar
  28. 28.
    Uden PC, Boakye HT, Kahakachchi C et al (2004) Element selective characterization of stability and reactivity of selenium species in selenized yeast. J Anal At Spectrom 19:65–73CrossRefGoogle Scholar
  29. 29.
    Klein EA, Thompson IM, Lippman SM et al (2001) SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E cancer prevention trial. J Urol 166:1311–1315CrossRefGoogle Scholar
  30. 30.
    Cook ED (2002) Selenium and vitamin e cancer prevention trial--this one’s for us. J Natl Med Assoc 94:856–858PubMedPubMedCentralGoogle Scholar
  31. 31.
    Lippman SM, Klein E, Goodman PJ et al (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin e cancer prevention trial (SELECT). JAMA 301:39–51CrossRefGoogle Scholar
  32. 32.
    Sharma AK, Amin S (2013) Post SELECT: selenium on trial. Future Med Chem 5:163–174CrossRefGoogle Scholar
  33. 33.
    Lü J, Zhang J, Jiang C et al (2016) Cancer chemoprevention research with selenium in the post-SELECT era: promises and challenges. Nutr Cancer 268:1–17CrossRefGoogle Scholar
  34. 34.
    Stewart M, Neldner K, Spallholz JE et al (1999) Selenite, selenocystamine, and selenomethionine have disparate abilities to impose oxidative stress and induce apoptosis in mouse keratinocytes. Free Radic Biol Med 26:42–48CrossRefGoogle Scholar
  35. 35.
    Poirier KA, Milner JA (1979) The effect of various seleno-compounds on Erlich ascites tumor cells. Bio Trace Elem Res 1:25–34CrossRefGoogle Scholar
  36. 36.
    Greeder GA, Milner JA (1980) Factors influencing the inhibitory effect of selenium on mice inoculated with Erlich ascites tumor cells. Science 209:825–827CrossRefGoogle Scholar
  37. 37.
    Drake EN (2006) Cancer chemoprevention: selenium as a prooxidant, not an antioxidant. Med Hypotheses 67:318–322CrossRefGoogle Scholar
  38. 38.
    Watrach AM, Milner JA, Watrach MA et al (1984) Inhibition of human breast cancer cells by selenium. Cancer Lett 25:41–47CrossRefGoogle Scholar
  39. 39.
    Fico ME, Poirier KA, Watrach AM, Watrach MA, Milner JA (1986) Differential effects of selenium on normal and neoplastic canine mammary cells. Cancer Res 46:3384–3388PubMedGoogle Scholar
  40. 40.
    Marshall JR, Burk RF, Payne OR et al (2017) Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men. Oncotarget 8:26312–26322CrossRefGoogle Scholar
  41. 41.
    Suganya K, Govindan K, Prabha P et al (2017) An extensive review on L-methioninase and its potential applications. Biocatal Agric Biotechnol 12:104–115CrossRefGoogle Scholar
  42. 42.
    Hoshiya Y, Guo H, Kubota T et al (1995) Human tumors are methionine dependent in vivo. Anticancer Res 15:717–718Google Scholar
  43. 43.
    Cavuoto P, Fenech MF (2012) A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension. Cancer Treat Rev 38:726–736CrossRefGoogle Scholar
  44. 44.
    Cellarier E, Durando X, Vasson MP et al (2003) Methionine dependency and cancer treatment. Cancer Treat Rev 29:489–499CrossRefGoogle Scholar
  45. 45.
    Hoffman RM (2015) Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: a 40-year odyssey. Expert Opin Biol Ther 15:21–31CrossRefGoogle Scholar
  46. 46.
    Tan Y, Xu M, Guo H, Sun X, Kubota T, Hoffman RM (1996) Anticancer efficacy of methioninase in vivo. Anticancer Res 16:3931–3936Google Scholar
  47. 47.
    Gupta A, Miki K, Xu M, Yamamoto N, Moossa AR, Hoffman RM (2003) Combination efficacy of doxorubicin and adenoviral methioninase gene therapy with prodrug selenomethionine. Anticancer Res 23:1181–1188PubMedGoogle Scholar
  48. 48.
    Sato D, Nozaki T (2009) Methionine gamma-lyase: the unique reaction mechanism, physiological roles, and therapeutic applications against infectious diseases and cancers. IUBMB Life 61:1019–1028CrossRefGoogle Scholar
  49. 49.
    Ip C, Thompson HJ, Zhu Z et al (2000) In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 60:2882–2886PubMedGoogle Scholar
  50. 50.
    Miki K, Xu M, Gupta A et al (2001) Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. Cancer Res 61:6805–6810PubMedGoogle Scholar
  51. 51.
    Yamamoto N, Gupta A, Xu M et al (2003) Methioninase gene therapy with selenomethionine induces apoptosis in bcl-2-overproducing lung cancer cells. Cancer Gene Ther 10:445–450CrossRefGoogle Scholar
  52. 52.
    Spallholz JE, Palace VP, Reid TW (2004) Methioninase and selenomethionine but not Se-methylselenocysteine generates methylselenol and superoxide in an in vitro chemiluminescent assay: implications for the nutritional carcinostatic activity of selenoamino acids. Biochem Pharmacol 67:47–554CrossRefGoogle Scholar
  53. 53.
    Levander OA, Morris VC, Higgs DJ (1973) Acceleration of thiol-induced swelling of rat liver mitochondria by selenium. Biochemistry 12:4586–4590CrossRefGoogle Scholar
  54. 54.
    Cooper AJL, Bruschi SA, Irirarte-Marino A et al (2002) Mitochondrial aspartate aminotransferase catalysis cysteine S-conjugate β-lyase reactions. Biochem J 368:253–261CrossRefGoogle Scholar
  55. 55.
    Keizer HG, Pinedo HM, Schuurhuis GJ et al (1990) Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 47:219–231CrossRefGoogle Scholar
  56. 56.
    Suzuki KT, Kurasaki K, Suzuki N (2007) Selenocysteine beta-lyase and methylselenol demethylase in the metabolism of e-methylated selenocompounds into selenide. Biochim Biophys Acta 1770:1053–1061CrossRefGoogle Scholar
  57. 57.
    Chen L (1997) Cytotoxicity of antibody-selenium immunoconjugates against erythrocytes and cancer cells. Doctoral Dissertation, Texas Tech UniversityGoogle Scholar
  58. 58.
    Cooper AJ, Krasnikov BF, Niatsetskaya ZV et al (2011) Cysteine S-conjugate β-lyases: important roles in the metabolism of naturally occurring sulfur and selenium-containing compounds, xenobiotics and anticancer agents. Amino Acids 41:7–27CrossRefGoogle Scholar
  59. 59.
    Reid TW, Grey T, Spallholz JE (2003) A comparison of the ability of se-methylselenocysteine and selenomethionine to kill human prostate cancer cells in vitro. NIH Symposium on Selenium Proteins, Abstract/Poster; Bethesda, MDGoogle Scholar
  60. 60.
    Medina D, Thompson H, Ganther H et al (2001) Se-methylselenocysteine: a new compound for chemoprevention of breast cancer. Nutr Cancer 40(1):12–17CrossRefGoogle Scholar
  61. 61.
    Jiang C, Wang Z, Ganther H et al (2001) Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 61:3062–3070PubMedGoogle Scholar
  62. 62.
    Lu Z, Qi L, Li GX et al (2015) Se-methylselenocysteine suppresses the growth of prostate cancer cell DU145 through annexin 43-induced apoptosis. J Cancer Res Ther 11:840–845CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Departments of Nutritional SciencesTexas Tech UniversityLubbockUSA

Personalised recommendations